Results 191 to 200 of about 156,800 (338)
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper +7 more
wiley +1 more source
Cryo-EM of autoantibody-bound NMDA receptors reveals antigenic hotspots in an active immunization model of anti-NMDAR encephalitis. [PDF]
Kim J +4 more
europepmc +1 more source
Pediatric N-methyl-d-aspartate receptor autoimmune encephalitis
openaire +2 more sources
Opinion: Inhibition of Blood-Brain Barrier Repair as a Mechanism in HIV-1 Disease. [PDF]
Maubert, Monique E. +2 more
core +2 more sources
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden +10 more
wiley +1 more source
Single-array measurements reveal non-uniform, mosaic-like chemosensory arrays in bacteria. [PDF]
Frank V, Livne N, Koler M, Vaknin A.
europepmc +1 more source
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley +1 more source

